Educated Enough to Make a Difference

Wharton School, University of Pennsylvania

GGSIP University, Delhi, India

Founder & CEO at AUM LifeTech [We are Hiring]

Philadelphia, Pennsylvania, United States

AUM LifeTech is an American Biotechnology company focused on the development of personalized medicine at the genetic level. AUM has developed the next generation of genomics tools in the area of gene silencing and regulation. Our innovative technology has applications in treating genetic disorders by development of Nucleic Acid Therapeutics based Precision Medicine. AUM LifeTech's goal is therapeutic innovation leading to a medical revolution for a better life.

AUM LifeTech

Founder and Chief Executive Officer

AUM BioTech is an American Biotechnology company focused on the development of next generation of innovative genomics tools in the area of gene silencing and regulation for biomedical research. Our next generation genetic research tools are globally being used by biomedical scientists and researchers working on basic, transitional and pre-clinical research.

AUM BioTech

Founder and Customer Happiness Officer

Member of the Editorial Board of journal Molecular Therapy — Nucleic Acids (Cell <a href="http://Press)http://www.cell.com/molecular-therapy-family/homeMolecular">Press)http://www.cell.com/molecular-therapy-family/homeMolecular</a> Therapy — Nucleic Acids is an international, open-access journal publishing top-quality basic, translational and clinical research in the broad fields of nucleic acid-based therapeutics to treat and/or correct genetic and acquired disease. As an official journal of the American Society of Gene & Cell Therapy, Molecular Therapy — Nucleic Acids will build upon the success of Molecular Therapy in publishing important peer-reviewed research and cutting-edge reviews and commentaries targeted to advances in gene- and oligonucleotide-based therapies. Subject areas include, but are not limited to: development of therapeutics based on nucleic acids and their derivatives, vector development and design for the delivery of RNA based therapeutics, applications of gene modifying agents including triplex forming oligonucleotides and enzymes such as Zn finger nucleases, pre-clinical target validation, safety/efficacy studies, and clinical trials.

Cell Press

Member of the Editorial Board

Oncogene – celebrates 20 years of shaping the scientific community and publishing the latest developments in cancer research.Oncogene covers all aspects of the structure and function of oncogenes, especially:Cellular oncogenes and their mechanism of activationStructure and function of their encoded proteinsOncogenes of the DNA and RNA tumour virusesThe molecular oncology of human tumoursTumour suppressor genesGrowth regulatory genesCell cycle controlGrowth factors and receptorsApoptosisImmortalisation and cellular senescence

Nature Publishing Group

Reviewer - Oncogene

The Journal of Molecular Biology provides high quality, comprehensive and broad coverage in all areas of molecular biology. The journal publishes original scientific research papers that provide functional and mechanistic insights and report a significant advance to the field. The journal encourages the submission of multidisciplinary studies that use complementary experimental and computational approaches to address challenging biological questions.In addition to research Communications and Articles, the journal welcomes submission of Methods Notes, Databases/ Web Servers, Brevia, Perspectives and Reviews.Research areas include but are not limited to:DNA replication, repair and recombination, gene expression, epigenetics and chromatin structure and function, RNA processing, functions of non coding RNAs, transcriptionStructure, chemistry, processing and function of biologically important macromolecules and complexesBiomolecular interactions, systems biologyComputational biologyTranslation, protein folding, processing and degradationSorting, spatiotemporal organization, trafficking, signal transduction and intracellular signallingMembrane processes, cell surface proteins and cell-cell interactionsMolecular basis of diseaseMethodological advances, both experimental and theoretical, including databases

Elsevier

Referee - Journal of Molecular Biology

Oligonucleotide Therapeutics Society (OTS) is world's leading forum dedicated to foster academia and industry-based research and development of oligonucleotide/nucleic acid based <a href="http://therapeutics.http://www.oligotherapeutics.orghttp://www.oligotherapeutics.org/scientific-advisory-council/">therapeutics.http://www.oligotherapeutics.orghttp://www.oligotherapeutics.org/scientific-advisory-council/</a>

Oligonucleotide Therapeutics Society

Member of the Scientific Advisory Council

BMC Genomics is an open access, peer-reviewed journal that considers articles on all aspects of genome-scale analysis, functional genomics, and proteomics.It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.

BioMed Central

Invited Manuscript Reviewer & Referee for BMC Genomics

Participated in a business building program (@ Wharton Entrepreneurship) with a focus on the following key aspects:1) Business development and strategy2) Revenue models and cash flow3) Operations management4) Strategic alliances5) Marketing

The Wharton School

Program participant

- Work on antisense technology and cancer biology led to the competitive & prestigious Young Scientist Award by the reputed Keystone Symposia in the form of - "Future of Science Fund Scholarship" for exceptional innovative research. The award was given in January, 2012

Temple University

Visiting Research Scholar

Perelman School of Medicine, University of Pennsylvania

Research

- Invited book chapter:• Invited to write a chapter* in Springer's special volume - "Nucleic Acid Drugs". This book is a special edition and exclusively contains invited chapters from scientific leaders (in their respective fields) from across the world both from academia and industry.- This invited article entails latest data and thoughts on the development & clinical applications of Nucleic Acid Therapeutics. *Also the corresponding and first author for this article. ๏ Book chapter (indirect invitation):• Wrote a chapter in Springer's book - "RNA technologies and their application".- The article entails data and thoughts on mRNA structure and its effect on post transcriptional gene silencing.๏ Research:• Worked on strategies to enhance siRNA delivery, stability and reduce off target effects in cell lines and hematopoietic stem cells (joint work published in the journal - Nucleic Acids Research; impact factor 8.026).• Assisted my mentor in reviewing research articles and to write NIH research grants

Visiting Scholar

- Work on microsatellites (junk DNA) led to a first author publication in the journal - Nucleic Acids Research (impact factor - 9.1).๏ Assisted in reviewing research articles

GGSIP University

Voluntary Research

- Teaching assistant in Bio-analytical Techniques - Assisted practical classes which involved graduate level genomics, recombinant DNA Technology and bioprocess engineering

Teaching assistant

- Teaching assistant in Genetics - Assisted practical classes with graduate level genetics

- Work on microsatellites (junk DNA) led to two publications in the following journals:• BMC Genomics (first author; impact factor 4.07).• Molecular Genetics and Genomics (second author; impact factor 2.635).• Work on microsatellites (junk DNA) led to a first author publication in the journal - Nucleic Acids Research (impact factor - 9.1).๏ Assisted in reviewing research articles

Veenu Aishwarya